Sei Investments Co. purchased a new stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 2,007 shares of the biopharmaceutical company’s stock, valued at approximately $125,000.
Several other institutional investors have also recently modified their holdings of the company. Russell Investments Group Ltd. lifted its holdings in shares of Ultragenyx Pharmaceutical by 11.4% in the second quarter. Russell Investments Group Ltd. now owns 31,184 shares of the biopharmaceutical company’s stock valued at $1,937,000 after purchasing an additional 3,195 shares in the last quarter. Aperio Group LLC lifted its holdings in shares of Ultragenyx Pharmaceutical by 8.4% in the second quarter. Aperio Group LLC now owns 3,851 shares of the biopharmaceutical company’s stock valued at $239,000 after purchasing an additional 299 shares in the last quarter. Rockefeller Financial Services Inc. lifted its holdings in shares of Ultragenyx Pharmaceutical by 9.0% in the second quarter. Rockefeller Financial Services Inc. now owns 408,379 shares of the biopharmaceutical company’s stock valued at $25,365,000 after purchasing an additional 33,716 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Ultragenyx Pharmaceutical by 3.6% in the first quarter. Goldman Sachs Group Inc. now owns 417,440 shares of the biopharmaceutical company’s stock valued at $28,294,000 after purchasing an additional 14,583 shares in the last quarter. Finally, Point72 Asset Management L.P. bought a new stake in shares of Ultragenyx Pharmaceutical in the first quarter valued at about $5,422,000. Institutional investors own 96.18% of the company’s stock.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) opened at 50.27 on Wednesday. The firm’s market cap is $2.13 billion. The firm’s 50-day moving average price is $59.39 and its 200-day moving average price is $64.37. Ultragenyx Pharmaceutical Inc. has a 12 month low of $49.56 and a 12 month high of $91.35.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported ($1.72) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.73) by $0.01. During the same quarter in the prior year, the firm posted ($1.46) EPS. On average, equities research analysts expect that Ultragenyx Pharmaceutical Inc. will post ($7.21) EPS for the current fiscal year.
In other news, CEO Emil D. Kakkis bought 7,500 shares of the company’s stock in a transaction on Monday, August 28th. The shares were purchased at an average price of $52.52 per share, with a total value of $393,900.00. Following the transaction, the chief executive officer now directly owns 430,569 shares in the company, valued at $22,613,483.88. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. 9.20% of the stock is owned by company insiders.
Several analysts recently issued reports on RARE shares. BidaskClub upgraded Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a report on Tuesday, June 20th. Stifel Nicolaus reiterated a “buy” rating and set a $111.00 target price on shares of Ultragenyx Pharmaceutical in a report on Friday, June 30th. Sanford C. Bernstein started coverage on Ultragenyx Pharmaceutical in a report on Thursday, July 27th. They set a “market perform” rating and a $72.00 target price on the stock. HC Wainwright reiterated a “neutral” rating and set a $75.00 target price (up previously from $72.00) on shares of Ultragenyx Pharmaceutical in a report on Tuesday, August 8th. Finally, Zacks Investment Research lowered Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating and eight have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $74.00.
COPYRIGHT VIOLATION NOTICE: This article was originally published by Stock Observer and is the sole property of of Stock Observer. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://www.thestockobserver.com/2017/09/13/sei-investments-co-purchases-shares-of-2007-ultragenyx-pharmaceutical-inc-rare.html.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.
Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.